April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Hyperemia-associated Costs of Medication Changes in Glaucoma Patients Treated Initially with Prostaglandin Analogs
Author Affiliations & Notes
  • S. Kotak
    Pfizer, New York, New York
  • G. F. Schwartz
    Glaucoma Consultants, Baltimore, Maryland
  • J. Tan
    HealthCore, Inc., Wilmington, Delaware
  • Footnotes
    Commercial Relationships  S. Kotak, Pfizer, E; G.F. Schwartz, Pfizer, C; Pfizer, R; J. Tan, HealthCore, E.
  • Footnotes
    Support  Pfizer Inc
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 4088. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Kotak, G. F. Schwartz, J. Tan; Hyperemia-associated Costs of Medication Changes in Glaucoma Patients Treated Initially with Prostaglandin Analogs. Invest. Ophthalmol. Vis. Sci. 2009;50(13):4088.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Develop a model to estimate and compare hyperemia-related costs in glaucoma patients treated initially with latanoprost (LAT), bimatoprost (BIM), or travoprost (TRA) monotherapy.

Methods: : Patients with a diagnosis of glaucoma who were newly treated with LAT, BIM, or TRA monotherapy were identified (HealthCore Managed Care Database). Physician-reported rates of hyperemia and physician-driven transition rates (switch or discontinuation of therapy) related to reports of hyperemia were documented from chart reviews of 300 patients from the Glaucoma Adherence and Persistency Study. The per-patient direct cost (2008) due to hyperemia-driven change in therapy was calculated as the sum of the cost of the initial prescription plus the cost of the office visit where the patient was evaluated and the decision to change therapy was made. Costs were stratified by whether patients were hyperemia free or discontinued the initial therapy due to hyperemia.

Results: : From the sample of 13,977 newly treated patients, 8743 were started on prostaglandin monotherapy only (LAT, 5726; BIM, 1633; TRA, 1384). Across all treatment groups, costs among hyperemia-free patients were $73.67 versus $140.02 for those who discontinued the initial prostaglandin due to hyperemia. Per patient costs were lowest in the group treated initially with LAT. With LAT as the reference product, total per patient incremental costs due to hyperemia-driven change in therapy were $5.92 for BIM and $5.43 for TRA. Sensitivity analyses confirmed the robustness of findings to increases either in the incidence of hyperemia among LAT-treated patients or in the cost of LAT.

Conclusions: : Hyperemia results in increased overall costs in patients treated with LAT, BIM, and TRA. Treatment with LAT is associated with lower hyperemia-related costs than treatment with BIM or TRA.

Keywords: clinical (human) or epidemiologic studies: outcomes/complications • clinical (human) or epidemiologic studies: health care delivery/economics/manpower 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.